Compare Abbott Laboratories (ABT) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while YieldMax NVDA Option Income Strategy ETF trades at $12.52. The key difference: Abbott Laboratories pays a 2.63% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and Abbott Laboratories is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABT | NVDY | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $136.62 | $17.96 |
52-Week Low | $82.57 | $12.03 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NVDY trades at $12.19, up 0.58% on the day, with a bearish technical signal from moving averages but neutral oscillators. The fund generates weekly dividends from its covered call strategy on NVIDIA, with recent payouts ranging from $0.10 to $0.21 per share. News highlights debate whether the income strategy justifies sacrificing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums; risks include capped gains during NVIDIA rallies. The 1.09% fee and opportunity cost versus direct NVIDIA ownership are key considerations for income-focused investors amid bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
